| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Original Research Communications |
Background: Long-term maintenance of weight loss remains a therapeutic challenge in obesity treatment.
Objective: This multicenter, double-blind, placebo-controlled study was designed to test the hypothesis that orlistat, a gastrointestinal lipase inhibitor, is significantly more effective than a placebo in preventing weight regain.
Design: Obese subjects who lost 
8% of their initial body weight during a 6-mo lead-in of a prescribed hypoenergetic diet (4180-kJ/d deficit) with no adjunctive pharmacotherapy were randomly assigned to receive placebo, 30 mg orlistat, 60 mg orlistat, or 120 mg orlistat 3 times daily for 1 y in combination with a maintenance diet to help prevent weight regain. Of 1313 recruited subjects [body mass index (in kg/m2): 28–43], 729 subjects lost 8% of their initial body weight during the 6-mo weight-loss lead-in period and were enrolled in the double-blind phase.
Results: After 1 y, subjects treated with 120 mg orlistat 3 times daily regained less weight than did placebo-treated subjects (32.8 ± 4.5% compared with 58.7 ± 5.8% regain of lost weight; P < 0.001). Moreover, more subjects in the 120-mg orlistat group than in the placebo group regained 
25% of lost weight (47.5% of subjects compared with 29.9%). In addition, orlistat treatment (120 mg 3 times daily) was associated with significantly greater reductions in total and LDL-cholesterol concentrations than was placebo (P < 0.001).
Conclusion: The use of orlistat during periods of attempted weight maintenance minimizes weight readjustment and facilitates long-term improvement in obesity-related disease risk factors.
Key Words: Obesity • orlistat • lipase inhibition • weight loss • lipids • cardiovascular disease risk factors • weight maintenance • humans
This article has been cited by other articles:
|
|
 |
|
  C. Garcia Ulen, M. M. Huizinga, B. Beech, and T. A. Elasy Weight Regain Prevention Clin. Diabetes, July 1, 2008; 26(3): 100 - 113. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. H Barnett Review: Pharmacotherapy as part of a weight management programme: a UK perspective The British Journal of Diabetes & Vascular Disease, November 1, 2007; 7(6): 268 - 277. [Abstract] [PDF]
|
|
|
|
 |
|
 K. C. Dunican, A. R. Desilets, and R. J. DeBellis State of the Art Review: Long-term Pharmacotherapy for Overweight and Obesity: A Review of Sibutramine, Orlistat, and Rimonabant American Journal of Lifestyle Medicine, October 1, 2007; 1(5): 367 - 388. [Abstract] [PDF]
|
|
|
|
 |
|
 G. A. Bray and F. L. Greenway Pharmacological Treatment of the Overweight Patient Pharmacol. Rev., June 1, 2007; 59(2): 151 - 184. [Full Text] [PDF]
|
|
|
|
 |
|
 B. Richelsen, S. Tonstad, S. Rossner, S. Toubro, L. Niskanen, S. Madsbad, P. Mustajoki, and A. Rissanen Effect of Orlistat on Weight Regain and Cardiovascular Risk Factors Following a Very-Low-Energy Diet in Abdominally Obese Patients: A 3-year randomized, placebo-controlled study Diabetes Care, January 1, 2007; 30(1): 27 - 32. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Tsujita, H. Takaichi, T. Takaku, S. Aoyama, and J. Hiraki Antiobesity action of {epsilon}-polylysine, a potent inhibitor of pancreatic lipase J. Lipid Res., August 1, 2006; 47(8): 1852 - 1858. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. D. LeCheminant, D. J. Jacobsen, M. A. Hall, and J. E. Donnelly A Comparison of Meal Replacements and Medication in Weight Maintenance after Weight Loss J. Am. Coll. Nutr., October 1, 2005; 24(5): 347 - 353. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z. Li, M. Maglione, W. Tu, W. Mojica, D. Arterburn, L. R. Shugarman, L. Hilton, M. Suttorp, V. Solomon, P. G. Shekelle, et al. Meta-Analysis: Pharmacologic Treatment of Obesity Ann Intern Med, April 5, 2005; 142(7): 532 - 546. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Klein, L. E. Burke, G. A. Bray, S. Blair, D. B. Allison, X. Pi-Sunyer, Y. Hong, and R. H. Eckel Clinical Implications of Obesity With Specific Focus on Cardiovascular Disease: A Statement for Professionals From the American Heart Association Council on Nutrition, Physical Activity, and Metabolism: Endorsed by the American College of Cardiology Foundation Circulation, November 2, 2004; 110(18): 2952 - 2967. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. J. Orzano and J. G. Scott Diagnosis and Treatment of Obesity in Adults: An Applied Evidence-Based Review J Am Board Fam Med, September 1, 2004; 17(5): 359 - 369. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I J Hickman, J R Jonsson, J B Prins, S Ash, D M Purdie, A D Clouston, and E E Powell Modest weight loss and physical activity in overweight patients with chronic liver disease results in sustained improvements in alanine aminotransferase, fasting insulin, and quality of life Gut, March 1, 2004; 53(3): 413 - 419. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Tiikkainen, R. Bergholm, A. Rissanen, A. Aro, I. Salminen, M. Tamminen, K. Teramo, and H. Yki-Jarvinen Effects of equal weight loss with orlistat and placebo on body fat and serum fatty acid composition and insulin resistance in obese women Am. J. Clinical Nutrition, January 1, 2004; 79(1): 22 - 30. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. M. McTigue, R. Harris, B. Hemphill, L. Lux, S. Sutton, A. J. Bunton, and K. N. Lohr Screening and Interventions for Obesity in Adults: Summary of the Evidence for the U.S. Preventive Services Task Force Ann Intern Med, December 2, 2003; 139(11): 933 - 949. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. A van Baak, E. van Mil, A. V Astrup, N. Finer, L. F Van Gaal, J. Hilsted, P. G Kopelman, S. Rossner, W P. James, and W. H. Saris Leisure-time activity is an important determinant of long-term weight maintenance after weight loss in the Sibutramine Trial on Obesity Reduction and Maintenance (STORM trial) Am. J. Clinical Nutrition, August 1, 2003; 78(2): 209 - 214. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. S. Weigle Pharmacological Therapy of Obesity: Past, Present, and Future J. Clin. Endocrinol. Metab., June 1, 2003; 88(6): 2462 - 2469. [Full Text] [PDF]
|
|
|
|
|
|
R. Bergholm, M. Tiikkainen, S. Vehkavaara, M. Tamminen, K. Teramo, A. Rissanen, and H. Yki-Jarvinen Lowering of LDL Cholesterol Rather Than Moderate Weight Loss Improves Endothelium-Dependent Vasodilatation in Obese Women With Previous Gestational Diabetes Diabetes Care, June 1, 2003; 26(6): 1667 - 1672. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Feinle, D. O'Donovan, S. Doran, J. M. Andrews, J. Wishart, I. Chapman, and M. Horowitz Effects of fat digestion on appetite, APD motility, and gut hormones in response to duodenal fat infusion in humans Am J Physiol Gastrointest Liver Physiol, May 1, 2003; 284(5): G798 - G807. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. I. Berkowitz, T. A. Wadden, A. M. Tershakovec, and J. L. Cronquist Behavior Therapy and Sibutramine for the Treatment of Adolescent Obesity: A Randomized Controlled Trial JAMA, April 9, 2003; 289(14): 1805 - 1812. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. G. Shekelle, M. L. Hardy, S. C. Morton, M. Maglione, W. A. Mojica, M. J. Suttorp, S. L. Rhodes, L. Jungvig, and J. Gagne Efficacy and Safety of Ephedra and Ephedrine for Weight Loss and Athletic Performance: A Meta-analysis JAMA, March 26, 2003; 289(12): 1537 - 1545. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M Labib The investigation and management of obesity J. Clin. Pathol., January 1, 2003; 56(1): 17 - 25. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Yoshikawa, H. Shimoda, N. Nishida, M. Takada, and H. Matsuda Salacia reticulata and Its Polyphenolic Constituents with Lipase Inhibitory and Lipolytic Activities Have Mild Antiobesity Effects in Rats J. Nutr., July 1, 2002; 132(7): 1819 - 1824. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Z. Yanovski and J. A. Yanovski Obesity N. Engl. J. Med., February 21, 2002; 346(8): 591 - 602. [Full Text] [PDF]
|
|
|
|
 |
|
 T. A. Wadden, R. I. Berkowitz, D. B. Sarwer, R. Prus-Wisniewski, and C. Steinberg Benefits of Lifestyle Modification in the Pharmacologic Treatment of Obesity: A Randomized Trial Arch Intern Med, January 22, 2001; 161(2): 218 - 227. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. H Davidson Efficacy of antiobesity therapies Am. J. Clinical Nutrition, March 1, 2000; 71(3): 844 - 844. [Full Text] [PDF]
|
|
|
|
|
|
C. H Halsted Reply to MH Davidson, JW Anderson, EC Konz, and GL Blackburn Am. J. Clinical Nutrition, March 1, 2000; 71(3): 846 - 846. [Full Text] [PDF]
|
|
|
|
|
|
J. O Hill and L. J Aronne Reply to WJ McCarthy Am. J. Clinical Nutrition, March 1, 2000; 71(3): 847 - 848. [Full Text] [PDF]
|
|
|
|
|
|
J. W Anderson and E. C Konz Benefits and risks of antiobesity agents Am. J. Clinical Nutrition, March 1, 2000; 71 (3): 844 - 845. [Full Text] [PDF]
|
|
|
|
|
|
W. J McCarthy Orlistat and weight loss Am. J. Clinical Nutrition, March 1, 2000; 71 (3): 846 - 847. [Full Text] [PDF]
|
|
|
|
 |
|
 G. A. Bray and F. L. Greenway Current and Potential Drugs for Treatment of Obesity Endocr. Rev., December 1, 1999; 20(6): 805 - 875. [Abstract] [Full Text]
|
|
|
|
|
|
J. W. Anderson, S. Vichitbandra, W. Qian, and R. J. Kryscio Long-Term Weight Maintenance after an Intensive Weight-Loss Program J. Am. Coll. Nutr., December 1, 1999; 18(6): 620 - 627. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. H Halsted Is blockade of pancreatic lipase the answer? Am. J. Clinical Nutrition, June 1, 1999; 69(6): 1059 - 1060. [Full Text] [PDF]
|
|
|
|
|
|
S. Klein The war against obesity: attacking a new front Am. J. Clinical Nutrition, June 1, 1999; 69(6): 1061 - 1063. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
